Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD33 TRAILBody
- Development stage
- Preclinical
- Lead developer
- TRIO Pharmaceuticals
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CD33 TRAILBody is an antibody-based therapeutic candidate developed by Trio Biotech for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It utilizes the company's proprietary TRAILBody platform, which fuses a CD33-targeting antibody with TRAIL (TNF-related apoptosis-inducing ligand) to selectively induce apoptosis in CD33-positive malignant cells. By binding to CD33, the drug localizes to the tumor site and triggers the extrinsic cell death pathway through the activation of death receptors DR4 and DR5. This approach is designed to enhance efficacy and reduce off-target toxicity, positioning the agent for potential use as a first-line treatment or in combination with existing therapies. The program is currently in the IND-enabling stage.
- Other names
- CD33 TRAILBodyCD-33 TRAILBodyCD 33 TRAILBody
02
Targets
CD33 (Myeloid cell surface antigen CD33)TNFRSF10A (Death receptor 4)TNFRSF10B (DR5)
Beyond the preview
Go deeper on CD33 TRAILBody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD33 TRAILBody.